BioSpace News Archive

StageZero Life Sciences, Ltd., a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announced that Matthew Pietras has resigned as CFO and COO.

Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following investor conferences: Conference: Jefferies Healthcare Conference Format: Fireside chat and 1x1s Presentation Date/Time: Thursday, June 9th , 2022 at 8:30 a.m. ET.

The new Phadia 2500+ series of instruments is now available for autoimmune testing in the U.S. The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.

Rhinostics Inc. and Nexus Medical Labs recently received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for a molecular SARS-CoV-2 test enabling unsupervised self-collection.

Arrivo BioVentures announced today that the company has closed enrollment of a phase 2 clinical study with its most advanced program, SP-624, after having enrolled more than 300 patients with major depressive disorder.

Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.”

Galecto, Inc. today announced two poster presentations at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 3-7, 2022 in Chicago, IL.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced top-line clinical data from its Phase 1/2 trial of galinpepimut-S.

Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that it will host an investor and analyst briefing during the 2022 American Society of Clinical Oncology (ASCO) Annual meeting.

Devonian Health Group Inc. today announced the acceptance for publication of results from its positive phase 2 trial of Thykamine™ in patients with mild-to-moderate Atopic Dermatitis.